Pharmaceutical complex of the R-Farm Group of Companies in Azerbaijan successfully passed a certification audit of the Center for Analytical Expertise of the Ministry of Health of the Republic and confirmed its compliance with the principles and rules for appropriate production practice, including those common in the territory of the European Union (GMP EU) .
Thus, the plant became the first and only pharmitution in Azerbaijan, which received the GMP certificate (Good Manufacturing Practice).
During the audit, administrative units, factory laboratories and production areas were inspected. The plant will receive a certificate for a period of three years, covering secondary packaging and issuing quality control of the finished product.
In the framework of international GMP standards for pharmaceutical preparations, strict requirements are provided: high quality source material, the use of modern processing technologies, the presence of well-planned buildings and advanced equipment, high qualification engaged in personnel production.
In the European Union, GMP is mandatory to follow the standard, the fulfillment of the requirements of which is taken into account in the certification of pharmaceutical industries. Since January 2018, GMP standards have become binding on the Azerbaijani pharmaceutical market. In Azerbaijan, GMP standards are harmonized with standards operating in the territory of the European Union.
Recall, December 9, 2019 in the Pirallahin Industrial Park, with the support of the Azerbaijan Investment Company and the Ministry of Economy of Azerbaijan, a solemn ceremony of launching a manufacturing complex of the R-Farm Group of Companies was held.
Pharmaceutical complex “R-Farm” in Baku is one of the most modern production sites in the CIS. The area of the production site equipped with high-tech equipment is 4.6 hectares.
At the R-Farm site in Baku, medicines will be made for therapy of a number of socially significant diseases: oncological, cardiac, endocrine, hematological, antibacterial, viral and other. Also, access to advanced therapy will receive patients suffering from hepatitis C, diabetes, tuberculosis, including its aggressive stable forms.